Dimethylformamide

Dimethylformamide

SCHEMBL131192

C=C.CCOC(C)OCC.CN(C)C=O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
TSHR P16473 1/20 0.41
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylformamide SCHEMBL314310 0.95 LMNA (0.60) LMNATSHRTHRB
Dimethylformamide SCHEMBL133174 0.91 LMNA (0.55) LMNATSHRTHRB
Dimethylformamide SCHEMBL9464389 0.83 TSHR (0.47) LMNATSHRTHRB
Acetaldehyde SCHEMBL22361219 0.83 LMNA (0.63) LMNATSHRTHRB
Ethylene SCHEMBL4935788 0.80 LMNA (0.75) LMNATHRB
Ethylene SCHEMBL3362390 0.80 LMNA (0.86) LMNATHRB
Ethylene SCHEMBL555416 0.80 LMNA (0.86) LMNATHRB
Biphenyl SCHEMBL134670 0.79 LMNA (0.41) LMNATSHR
Acrolein SCHEMBL3930769 0.79 LMNA (0.57) LMNATSHRTHRB
Dimethylformamide SCHEMBL28172576 0.78 LMNA (0.39) LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716481-B2 Process for the preparation of 6-substituted-1-(2H)-isoquinolinones SANOFI (FR) 2014-05-06 US disclosed
EP-1727803-B1 PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N'-[3-(1H-PYRAZOL-5-YL)PHENYL] UREAS AND INTERMEDIATES THEREOF ARENA PHARM INC (US) 2012-03-07 EP disclosed
US-20110021779-A1 PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES SANOFI-AVENTIS (FR) 2011-01-27 US disclosed
EP-2240441-A1 PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES Sanofi-Aventis (FR) 2010-10-20 EP disclosed
US-7812176-B2 reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
WO-2009080335-A1 PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES SANOFI-AVENTIS (FR) 2009-07-02 WO disclosed
US-7312342-B2 Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)-methanone and salts thereof MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2007-12-25 US disclosed
US-20070293685-A1 reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2007-12-20 US disclosed
EP-1727803-A1 PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N'-[3-(1H-PYRAZOL-5-YL)PHENYL] UREAS AND INTERMEDIATES THEREOF Arena Pharmaceuticals, Inc. (US) 2006-12-06 EP disclosed
WO-2005103011-A1 PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N’-[3-(1H-PYRAZOL-5-YL) PHENYL] UREAS AND INTERMEDIATES THEREOF ARENA PHARMACEUTICALS, INC. (US) 2005-11-03 WO disclosed
EP-1353906-B1 PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF MERCK PATENT GMBH (DE) 2004-06-23 EP disclosed
WO-2004028450-A2 PROCESS OF MAKING PHENYLPYRAZOLES USEFUL AS SELECTIVE 5HT2A MODULATORS AND INTERMEDIATES THEREOF ARENA PHARMACEUTICALS, INC. (US) 2004-04-08 WO disclosed
US-20040063723-A1 Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)- methanone and salts thereof MERCK PATENT GMBH (DE) 2004-04-01 US disclosed
EP-1353906-A1 PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF MERCK PATENT GmbH (DE) 2003-10-22 EP disclosed
WO-2002059092-A1 PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF MERCK PATENT GMBH (DE) 2002-08-01 WO disclosed
US-3976639-A Intermediates for indoles HOFFMANN-LA ROCHE INC. (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021779-A1 PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES CYP1B1, CYP1A1, NQO1 LMNA 1159/4885TSHR 4350/4885THRB 4527/4885
US-20040063723-A1 Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)- methanone and salts thereof TPH1, TPH2, IDO1 LMNA 1134/4885TSHR 2436/4885THRB 2872/4885
US-20070293685-A1 reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators HTR5A, HTR2C, HTR2A LMNA 3513/4885TSHR 91/4885THRB 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.